ROCKETML, INC.

Biotech

Computational platform for analyzing single-cell genomic data to predict drug treatment response by identifying patient-specific cell type phenotypes

Grants
$706K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Large Scale And Automated Unsupervised Machine Learning For Anomaly Detection$225,000
Federal grantDepartment of Health and Human Services · Phase I · Ultra-Fast Combinatorial Analysis for Biomarker Discovery$225,000
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Empowering Discovery of COVID-19 Vaccine through Large Scale Unsupervised Deeplearning for Electron Microscopy Data$256,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2986Whisper Biosciences——
2987Singular Genomics——
2988SYNTIRON, LLC.——
2989ROCKETML, INC.——
2990ATHGHIN BIOTECHNOLOGY, INC.——
2991Twentyeight-Seven Therapeutics——
2992VASADE BIOSCIENCES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.